Semaglutide Changing the Future of Metabolic Care

On 27th March, a focused CME session highlighted how newer molecules like GLP-1 receptor agonists are reshaping the management of metabolic conditions. While repurposing medications is common in modern medicine, this shift stands out due to its strong scientific backing and wide-ranging clinical impact.

Initially introduced for diabetes management, Semaglutide has now demonstrated benefits beyond blood sugar control. It is widely used for weight management and is gaining attention for its role in reducing inflammation and fibrosis in fatty liver disease. Its potential also extends to conditions like CKM syndrome and areas such as addiction-related neurobiology.

The session provided a clear and practical overview of Semaglutide therapy, covering key aspects such as real-world applications, common misconceptions, appropriate usage, and important do’s and don’ts. The CME was insightful, well-structured, and highly engaging.